Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,578.03
-21.2968-1.33%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,598.74
Open:1,598.63
Low:1,570.99
Close:1,599.33
Volume:60.92M
Turnover:5.19B
Market Cap:1.64T
Float Cap:1.58T

Loading ...

NYSE Most Active Issues

Dow Jones
·
Yesterday

Moderately bullish activity in Novo Nordisk with shares down 1.06%

TIPRANKS
·
Yesterday

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

TIPRANKS
·
Yesterday

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

TIPRANKS
·
Yesterday

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Yesterday

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Yesterday

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Novo Nordisk announces new data on CagriSema

TIPRANKS
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30